Loading...

D. Western Therapeutics Institute

DB:6DW
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
6DW
DB
¥13B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

D. Western Therapeutics Institute, Inc., a biotechnology company, develops drugs to serve patients worldwide. The last earnings update was 22 days ago. More info.


Add to Portfolio Compare Print
  • D. Western Therapeutics Institute has significant price volatility in the past 3 months.
6DW Share Price and Events
7 Day Returns
1.2%
DB:6DW
-1.4%
DE Biotechs
2.4%
DE Market
1 Year Returns
-11.3%
DB:6DW
-10.6%
DE Biotechs
-6.2%
DE Market
6DW Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
D. Western Therapeutics Institute (6DW) 1.2% -26.3% -27.7% -11.3% -29.5% -31.3%
DE Biotechs -1.4% 2.6% -7.7% -10.6% 54.2% 8%
DE Market 2.4% 3% 7.4% -6.2% 9.6% 14.1%
1 Year Return vs Industry and Market
  • 6DW underperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
6DW
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for D. Western Therapeutics Institute's competitors could be found in our database.

6DW Value

 Is D. Western Therapeutics Institute undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for D. Western Therapeutics Institute. This is due to cash flow or dividend data being unavailable. The share price is €3.53.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for D. Western Therapeutics Institute's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are D. Western Therapeutics Institute's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:6DW PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in JPY ¥-28.47
JASDAQ:4576 Share Price ** JASDAQ (2019-04-18) in JPY ¥495
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.41x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.67x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of D. Western Therapeutics Institute.

DB:6DW PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= JASDAQ:4576 Share Price ÷ EPS (both in JPY)

= 495 ÷ -28.47

-17.38x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • D. Western Therapeutics Institute is loss making, we can't compare its value to the Europe Biotechs industry average.
  • D. Western Therapeutics Institute is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does D. Western Therapeutics Institute's expected growth come at a high price?
Raw Data
DB:6DW PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -17.38x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for D. Western Therapeutics Institute, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on D. Western Therapeutics Institute's assets?
Raw Data
DB:6DW PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in JPY ¥47.92
JASDAQ:4576 Share Price * JASDAQ (2019-04-18) in JPY ¥495
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.85x
DB:6DW PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= JASDAQ:4576 Share Price ÷ Book Value per Share (both in JPY)

= 495 ÷ 47.92

10.33x

* Primary Listing of D. Western Therapeutics Institute.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • D. Western Therapeutics Institute is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess D. Western Therapeutics Institute's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. D. Western Therapeutics Institute has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

6DW Future Performance

 How is D. Western Therapeutics Institute expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as D. Western Therapeutics Institute has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.5%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is D. Western Therapeutics Institute expected to grow at an attractive rate?
  • Unable to compare D. Western Therapeutics Institute's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare D. Western Therapeutics Institute's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare D. Western Therapeutics Institute's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:6DW Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:6DW Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in JPY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:6DW Future Estimates Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
DB:6DW Past Financials Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income *
2018-12-31 292 -540 -748
2018-09-30 267 -798
2018-06-30 293 -635 -605
2018-03-31 279 -1,578
2017-12-31 254 -797 -1,563
2017-09-30 239 -1,398
2017-06-30 151 -610 -1,464
2017-03-31 126 -385
2016-12-31 168 -333 -253

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if D. Western Therapeutics Institute is high growth as no earnings estimate data is available.
  • Unable to determine if D. Western Therapeutics Institute is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:6DW Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from D. Western Therapeutics Institute Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:6DW Future Estimates Data
Date (Data in JPY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
DB:6DW Past Financials Data
Date (Data in JPY Millions) EPS *
2018-12-31 -28.47
2018-09-30 -30.38
2018-06-30 -23.04
2018-03-31 -60.09
2017-12-31 -59.87
2017-09-30 -54.33
2017-06-30 -57.73
2017-03-31 -15.46
2016-12-31 -10.44

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if D. Western Therapeutics Institute will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine D. Western Therapeutics Institute's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. D. Western Therapeutics Institute's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. D. Western Therapeutics Institute's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess D. Western Therapeutics Institute's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
D. Western Therapeutics Institute has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

6DW Past Performance

  How has D. Western Therapeutics Institute performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare D. Western Therapeutics Institute's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • D. Western Therapeutics Institute does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare D. Western Therapeutics Institute's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare D. Western Therapeutics Institute's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
D. Western Therapeutics Institute's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from D. Western Therapeutics Institute Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:6DW Past Revenue, Cash Flow and Net Income Data
Date (Data in JPY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 292.00 -748.00 268.00 795.00
2018-09-30 267.00 -798.00 269.00 823.00
2018-06-30 293.00 -605.00 269.00 753.00
2018-03-31 279.00 -1,578.00 263.00 675.00
2017-12-31 254.00 -1,563.00 276.00 603.00
2017-09-30 239.00 -1,398.00 276.00 459.00
2017-06-30 151.00 -1,464.00 276.00 338.00
2017-03-31 126.00 -385.00 266.00 284.00
2016-12-31 168.00 -253.00 260.00 226.00
2015-12-31 61.00 -296.00 195.00 143.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if D. Western Therapeutics Institute has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if D. Western Therapeutics Institute has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if D. Western Therapeutics Institute improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess D. Western Therapeutics Institute's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
D. Western Therapeutics Institute has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

6DW Health

 How is D. Western Therapeutics Institute's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up D. Western Therapeutics Institute's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • D. Western Therapeutics Institute is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • D. Western Therapeutics Institute's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of D. Western Therapeutics Institute's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from D. Western Therapeutics Institute Company Filings, last reported 3 months ago.

DB:6DW Past Debt and Equity Data
Date (Data in JPY Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 1,299.00 600.00 1,584.00
2018-09-30 1,498.00 600.00 1,670.00
2018-06-30 1,715.00 600.00 1,888.00
2018-03-31 1,899.00 600.00 2,083.00
2017-12-31 2,094.00 600.00 2,132.00
2017-09-30 2,336.00 600.00 2,190.00
2017-06-30 2,446.00 600.00 2,319.00
2017-03-31 3,555.00 600.00 3,886.00
2016-12-31 2,876.00 0.00 2,644.00
2015-12-31 2,111.00 0.00 1,929.00
  • D. Western Therapeutics Institute's level of debt (46.2%) compared to net worth is high (greater than 40%).
  • Unable to establish if D. Western Therapeutics Institute's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • D. Western Therapeutics Institute has sufficient cash runway for 2.9 years based on current free cash flow.
  • D. Western Therapeutics Institute has sufficient cash runway for 2.5 years if free cash flow continues to grow at historical rates of 20% each year.
X
Financial health checks
We assess D. Western Therapeutics Institute's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. D. Western Therapeutics Institute has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

6DW Dividends

 What is D. Western Therapeutics Institute's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from D. Western Therapeutics Institute dividends.
If you bought €2,000 of D. Western Therapeutics Institute shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate D. Western Therapeutics Institute's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate D. Western Therapeutics Institute's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:6DW Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:6DW Future Dividends Estimate Data
Date (Data in ¥) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as D. Western Therapeutics Institute has not reported any payouts.
  • Unable to verify if D. Western Therapeutics Institute's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of D. Western Therapeutics Institute's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as D. Western Therapeutics Institute has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess D. Western Therapeutics Institute's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can D. Western Therapeutics Institute afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. D. Western Therapeutics Institute has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

6DW Management

 What is the CEO of D. Western Therapeutics Institute's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Hiroyoshi Hidaka
AGE 80
CEO Bio

Dr. Hiroyoshi Hidaka, M.D., Ph.D. founded D.Western Therapeutics Institute in 1999 and has been its Chairman since June 2012 and also has been chief Science Officer Since June, 2010 and serves as its Chief Executive Officer. Dr. Hidaka serves as a Manager of Research and Development Center, Director of DWTI since December 2004. Mr. Hidaka has been Guest Professor at Duke University, U.S. since July 1998. He served as Chief Technology Officer of D.Western Therapeutics Institute and served as its Chief Science Officer since June 2010. He served as an Associate Professor, Faculty of Medicine at Kyoto University since April 1976, as Professor, Faculty of Medicine at Mie University since January 1978 and as Professor, Faculty of Medicine at Nagoya University since August 1987. Mr. Hidaka was a Professor at Nagoya University School of Medicine and an Adjunctive Professor at Duke University Medical Center. He has been an Executive Director of D.Western Therapeutics Institute since December 2004. He holds an M.D. and Ph.D. from Nagoya University School of Medicine.

CEO Compensation
  • Insufficient data for Hiroyoshi to compare compensation growth.
  • Insufficient data for Hiroyoshi to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team

Hiroyoshi Hidaka

TITLE
Founder
AGE
80

Yuichi Hidaka

TITLE
President
AGE
45

Tetsuya Kawakami

TITLE
GM of Administration Division & Director
AGE
53
Board of Directors Tenure

Average tenure and age of the D. Western Therapeutics Institute board of directors in years:

8
Average Tenure
54.5
Average Age
  • The tenure for the D. Western Therapeutics Institute board of directors is about average.
Board of Directors

Hiroyoshi Hidaka

TITLE
Founder
AGE
80
TENURE
6.8 yrs

Yuichi Hidaka

TITLE
President
AGE
45
TENURE
10.3 yrs

Tetsuya Kawakami

TITLE
GM of Administration Division & Director
AGE
53
TENURE
5.1 yrs

Yoshiyuki Yamakawa

TITLE
Outside Director
AGE
56
TENURE
9.1 yrs

Tasuku Honjyo

TITLE
Member of Scientific Advisory Board

Masaaki Suzuki

TITLE
Member of Scientific Advisory Board

Masato Shibuya

TITLE
Member of Scientific Advisory Board

Arata Uemura

TITLE
Member of Scientific Advisory Board

Anthony Means

TITLE
Member of Scientific Advisory Board

Walter Chazin

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess D. Western Therapeutics Institute's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. D. Western Therapeutics Institute has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

6DW News

Simply Wall St News

6DW Company Info

Description

D. Western Therapeutics Institute, Inc., a biotechnology company, develops drugs to serve patients worldwide. The company offers GLANATEC, an ophthalmic solution for the treatment of glaucoma/ocular hypertension. It is also developing K-134, an anti-platelet that has completed phase IIb trial for the treatment of arteriosclerosis obliterans; WP-1303(H-1129), which has completed phase II trial for the treatment of glaucoma/ocular hypertension; H-1337, a multikinase inhibitor, which has completed phase I/IIA clinical trials for the treatment of glaucoma and ocular hypertension; and DW-1002, an ophthalmic surgical adjuvant for the cataract surgeries, and ILM staining and peeling. In addition, the company is developing ophthalmic analgesic. The company was founded in 1999 and is headquartered in Nagoya, Japan.

Details
Name: D. Western Therapeutics Institute, Inc.
6DW
Exchange: DB
Founded: 1999
¥103,324,706
26,275,200
Website: http://www.dwti.co.jp
Address: D. Western Therapeutics Institute, Inc.
CK21 Hirokoujifushimi Building,
7th Floor,
Nagoya,
Aichi, 460-0003,
Japan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
JASDAQ 4576 Common Shares TSE JASDAQ JP JPY 23. Oct 2009
DB 6DW Common Shares Deutsche Boerse AG DE EUR 23. Oct 2009
Number of employees
Current staff
Staff numbers
17
D. Western Therapeutics Institute employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 21:21
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/02/14
Last earnings filing: 2019/03/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.